Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

TLR3 activation helps improve skin and hair follicle healing in mice.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.

Targeted cytokine treatments may help with alopecia areata, but more research is needed.

STAT3 signaling is important for healthy skin and hair follicles, and its disruption can lead to skin conditions like atopic dermatitis.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

Potential compounds may inhibit hair loss by targeting a non-androgen pathway.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Engineered cytokines show promise for improving tissue healing and safety in regenerative medicine.

Loss of Dnmt3a and Dnmt3b increases aggressive skin tumors by affecting PPAR-γ.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Ketoconazole lotion can improve hair regrowth for some people with androgenetic alopecia.

Tislelizumab can cause cutaneous lupus erythematosus.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Quercitrin may help treat Alzheimer's by boosting brain cell signaling without causing tumors.

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.

Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

MEGA PROTAC improves prediction and ranking of protein complexes better than existing methods.

The inhibitor affects androgen metabolism but not ovarian function.

Cepharanthine and berbamine may affect SK channels, influencing their therapeutic effects.